VEREGEN (sinecatechins) by ANI Pharmaceuticals is unknown. First approved in 2006.
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
VEREGEN (sinecatechins) is a topical ointment approved in 2006 for external genital warts, derived from green tea extract with proposed anti-oxidative mechanisms. The exact clinical mechanism of action remains unknown, limiting differentiation in the marketplace. It represents a botanical/natural product approach to a viral skin condition.
Minimal team investment expected; brand likely operating with skeleton crew ahead of patent expiry in October 2026.
unknown. In vitro, sinecatechins had anti-oxidative activity; the clinical significance of this finding is unknown.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers
Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage
Worked on VEREGEN at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
VEREGEN offers no meaningful career growth; the product is in terminal decline with <9 months to patent expiry and minimal market presence. Employment opportunities are limited to legacy support roles with declining headcount and budget.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo